eGAD! How I Learned to Stop Worrying and Love Cymbalta!

Pharma Marketing Blog represents the opinions of
John Mack
Publisher of
Pharma Marketing News.

We accept advertising relevant to the interests of our members.
For more information, see:

Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com

My Humble Opinion	Other People's Opinion
A "Must Read" Blog for Insiders. -- Wall Street Journal	A bi-weekly podcast. Listen and call-in live online or download to your iPod!

| Also see Pharma Marketing News OpEd Pieces |

eGAD! How I Learned to Stop Worrying and Love Cymbalta!

Posted: February 28, 2007

Like most Rx drugs these days, Cymbalta started life approved for one specific indication -- major depressive disorder -- and was later approved for another -- diabetic neuropathic pain -- and now yet another -- generalized anxiety disorder (GAD).

GAD is one of those "real medical conditions" that no one has heard of until a drug has been approved for its treatment.

Will Lilly, the marketer of Cymbalta, engage in a bit of GAD disease mongering to drive unsuspecting worriers to doctors' offices?

I think this is a possibility, based on what Lilly is getting away with in the current "Depression Hurts" marketing campaign.

To find out what I mean, please read, please read today's post to Pharma Marketing Blog.

For more posts in related topic areas, see:

If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.

| Return to Pharma Marketing Blog Topics |

Special Supplement
Direct-to-Consumer Advertising
Volume Two: DTC in the New Era

DTC advertising is set for major changes in light of public criticism, but also in reaction to the changing reality of the marketplace where there is less need for a one size fits all solution. DTC must evolve and marketers must pay more attention to measuring and improving its effectiveness. Otherwise, billions of dollars will continue to be wasted. This volume is devoted to DTC best practices with a focus on techniques for improving DTC efficacy and return on investment, which is generally considered to be declining.

TABLE OF CONTENTS

Order both Volume One and Volume Two and SAVE! (Click Here)

Order and pay for Volume Two now using your credit card.

ONLY $29.95
PDF file delivered to you by email (usually within minutes of placing your order):

If you wish to be pay by check or credit card off-line, please use:
Printable Order Form